G1XCGD (lentiviral vector transduced CD34+ cells) clinical trials

A phase I/II, non randomized, monocentric open-label study of autologous CD34+ cells transduced with the G1XCGD lentiviral vector in patients with X-linked chronic granulomatous disease

This study is testing a new gene therapy for X-linked Chronic Granulomatous Disease (X-CGD), a rare immune disorder. It uses a patient's own cells, modified in the lab, to help their immune system work better. Researchers are checking if it's safe and helps improve the body's ability to fight infections.